ExThera Medical Partners with Predicate Healthcare Performance Group to Expand Reach of Proven COVID-19 Treatment
ExThera & Predicate HPG secure commercial partnership agreement in United States
MARTINEZ, Calif. – ExThera Medical and Predicate Healthcare Performance Group (Predicate HPG) have entered into a commercial partnership agreement in the United States for ExThera’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100).
“In Predicate HPG’s ongoing efforts to deliver evidence-based, technology-enabled care to every patient, we are pleased to partner with ExThera Medical to provide clinicians with an effective, disease-modifying treatment option for COVID-19. Medical innovations, such as the Seraph 100 are indispensable in the delivery of high-quality care for critically ill patients,” said Morris Nguyen, Founder and CEO of Predicate Healthcare Performance Group.
The Seraph 100 is the first blood purification device to be shown to reduce both bacterial and viral loads in the bloodstream and has been used on more than 600 COVID-19 patients in the United States alone since April 2020. The device has been available under an Emergency Use Authorization in the United States since that time and has been shown in a preliminary clinical study to dramatically reduce mortality in severe COVID-19 cases.
“ExThera’s partnership with Predicate HPG expands the Seraph 100 reach and visibility in the US. Overworked clinicians now have a therapy for treating critically-ill COVID patients whereas previously they were often administering hospice care to these patients,” said Bob Ward, ExThera Medical Chairman and CEO.
About Predicate HPG
Predicate HPG is a healthcare advisory firm that develops strategies to reduce clinical variation, which is integral to decreasing overall costs and improving healthcare delivery globally. Through a breadth of experience in critical care, health economics, and process engineering, Predicate HPG collaborates with interdisciplinary stakeholders to tailor solutions that solves large-scale challenges at the national and individual hospital level. Using a unique multifaceted approach, the Predicate HPG Solutions Architecture™ creates unified clinical guidelines incorporating the most advanced medical technologies and reinforced by behavioral science to provide sustainable, evidence-based practice change.
For more information visit www.predicatehpg.com.
About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, or field hospitals to address bloodstream infections and sepsis regardless of the initial cause. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from severe infections. With a growing body of outcome and health economic evidence from independent clinical studies, participation in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US and EU, the company is well positioned to serve healthcare professionals and patients alike. The Seraph 100® is CE marked and commercially available in the EU, and has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.
For more information visit the company’s website at www.extheramedical.com.
About Seraph 100
As a patient’s blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby removed from the bloodstream. Seraph targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis. The ‘antithrombogenic’ heparin media can be combined with other ExThera-proprietary media to tailor the capability of future Seraph products for the treatment of specific diseases, or to further broaden Seraph’s capability.
For more news stories on the Seraph 100 click here.
All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.
L40143 Rev A